Sign in
Taking people in SwedenPhase 1/2

Tests adding hydroxyurea to salvage chemotherapy for returning or resistant acute myeloid leukemia

Tests adding hydroxyurea to combination treatment in adults with returning or resistant leukemia.

Key facts

Who runs it
Karolinska University Hospital
Where
Goteborg, Huddinge, Orebro, and Uppsala, SwedenSee the 4 sites
Registry title
FLAsH-IV-AML: A study evaluating the safety and effectiveness of adding hydroxyurea to treatment for adults with acute myeloid leukemia (AML) that has relapsed after treatment or has not responded to treatment
Status
Recruiting
Phase
Phase 1/2
People taking part
26 people, planned
Started
12 Oct 2026
Expected to end
30 Sept 2034
Type of study
Interventional
Record updated
14 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with acute myeloid leukemia (AML) that came back after treatment or did not respond to treatment. It tests adding hydroxyurea to a salvage treatment.

Age
18 years or older. The record also lists age 75 years or older as an exclusion.
Sex
All sexes can join.
Disease stage
Acute myeloid leukemia that did not respond to treatment (more than 10% blasts in the bone marrow after one cycle of intensive chemotherapy, or no complete remission after two cycles), or that has relapsed, or shows measurable residual disease at a level of 5% or more.
Earlier treatment
Fit for intensive chemotherapy. A relapse within 3 months after a donor stem-cell transplant (allo-HCT) is an exclusion.
Biomarker or test result
No TP53 double hit mutation or biallelic TP53 inactivation.

Main reasons for not taking part

  • Acute promyelocytic leukemia
  • Leukemia in the central nervous system (CNS)
  • White blood cell count of 30 or more, unless lowered with hydroxyurea in phase II
  • Uncontrolled infection
  • Serious heart problems, such as a heart attack in the last 3 months or heart failure grade III or IV

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • A diagnosis of either: • Refractory AML defined as having > 10% bone marrow blasts after induction with one cycle of intensive chemotherapy or no CR after two cycles of chemotherapy. • Relapsed disease (including extramedullary disease) according to the 2022 ELN criteria (see appendix A). • MRD relapse defined as evidence of measurable (minimal) residual disease (MRD) at a level of ≥5%, as determined by either validated genetic assays or multiparameter flow cytometry
  • The subject has given their written consent to participate in the trial
  • Patient is capable of giving informed consent
  • Age 18 years or older
  • ECOG Performance Status ≤ 2
  • Adequate renal and hepatic functions as indicated by the following laboratory values: - Creatinine clearance ≥ 30 mL/min calculated by the Cockcroft Gault formula. - Serum bilirubin ≤ 3 x upper limit of normal (ULN), unless due to Gilbert’s syndrome. - Alanine aminotransferase (ALAT) ≤ 5 x ULN
  • Considered fit for intensive chemotherapy
  • Male patients must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy and must agree to avoid fathering a child (while on therapy and for 6 months after the final study drug administration). In addition, their female partners of childbearing potential must use a highly effective method of birth control
  • Male patient must not donate sperm starting at screening and throughout the study period and for 6 months after the final study drug administration
  • Female patients of nonchildbearing potential must be postmenopausal (defined as at least 1 year without any menses), documented surgically sterile prior to screening
  • Female patients of childbearing potential must agree to avoid pregnancy during the study and for 6 months after the final study drug administration and have a negative urine or serum pregnancy test at screening, and if heterosexually active, agree to consistently apply one highly effective method of birth control in combination to a barrier method for the duration of the study and for 6 months after the final study drug administration

Who cannot take part

  • Known intolerance to any of the chemotherapeutic drugs in the protocol
  • Known inherited bone marrow failure syndromes (e.g., Fanconi anemia, Dyskeratosis congenita and related telomeropathies (e.g., TERT, TERC, DKC1 mutations)
  • Patients with a history of non-compliance to medical regimens or who are considered unreliable with respect to compliance
  • Uncontrolled infection
  • Major organ failure precluding administration of planned chemotherapy
  • WBC ≥30; pretreatment with HU to reduce the level of WBC <30 is allowed in part B/phase II of the trial
  • Cardiac dysfunction as defined by: o Myocardial infarction within the last 3 months of study entry, or o Reduced left ventricular function with an ejection fraction < 50% as measured by echocardiogram (will only be performed when clinically suspected) or o Unstable angina or o New York Heart Association (NYHA) grade III or IV congestive heart failure (see appendix C) or o Severe cardiac arrhythmias
  • Age 75 years or older
  • Acute promyelocytic leukemia
  • Positive pregnancy test
  • Lactating female or female of childbearing potential not using adequate contraception
  • TP53 double hit mutation / biallelic TP53 inactivation
  • CNS leukemia
  • Relapse within 3 months from the date of allo-HCT
  • ECOG Performance Status > 2

Where in Sweden

  • Sahlgrenska University Hospital-Vaestra GoetalandsregionenGoteborg, SwedenTaking people
  • Karolinska University HospitalHuddinge, SwedenTaking people
  • Region Oerebro LaenOrebro, SwedenTaking people
  • Uppsala University HospitalUppsala, SwedenTaking people

About the trial

What the trial wants to find out

Phase I (run-in): To assess the safety and tolerability of HU at two different dose-levels added to salvage AML therapy consisting of ara-C/fludarabine, idarubicin and venetoclax (frequency and severity of adverse events and dose-limiting toxicities; dose-finding). Phase II: To assess the impact of HU added to salvage AML therapy consisting of ara-C/fludarabine, idarubicin and venetoclax on the 1-year event-free survival (EFS) defined as from the time from initiation of study treatment to the first occurrence of treatment failure, hematologic relapse from CR/CRi, or death from any cause.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
FLAsH-IV-AML: A phase I/II multi-center study to assess the tolerability and efficacy of the addition of hydroxyurea to salvage treatment with fludarabine, ara-C, idarubicin and venetoclax for adults with relapsed or refractory acute myeloid leukemia
Plain-language title
Tests adding hydroxyurea to salvage chemotherapy for returning or resistant acute myeloid leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
14 July 2026